SCHEMBL2778053

SCHEMBL2778053

Cn1cc2c(C=CC(=O)O)cccc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
PARP1 P09874 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
GAA P10253 2/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 5/20 0.40
PKM P14618 1/20 0.39
ALDH1A1 P00352 3/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2778049 1.00 NPC1 (0.45) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL13705670 0.82 NPC1 (0.42) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL543543 0.81 NPC1 (0.44) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL10257233 0.81 NPC1 (0.44) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL15870921 0.80 CREBBP (0.34) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL544070 0.78 MEN1 (0.41) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL543348 0.78 USP7 (0.35) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL543347 0.78 USP7 (0.35) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL2778185 0.77 MIF (0.43) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL2778189 0.77 MIF (0.43) NPC1RAB9ANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2141150-B1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2013-12-11 EP disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 US disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH NPC1 1140/4885RAB9A 3544/4885NFKB1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.